Cargando…

Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study

PURPOSE: This retrospective analysis aimed to evaluate the clinical outcomes and cost-effectiveness of long-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia caused by chemotherapy for breast cancer. METHODS: Patients with breast cancer who received long- or short-ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yaqin, Zhao, Chenglong, Ma, Peizhi, Jiang, Dandan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827532/ https://www.ncbi.nlm.nih.gov/pubmed/36598048 http://dx.doi.org/10.1177/10732748221140289

Ejemplares similares

Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data
por: Zhao, Jie, et al.
Publicado: (2022)

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
por: Aapro, Matti, et al.
Publicado: (2017)

New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy
por: Theyab, Abdulrahman, et al.
Publicado: (2023)

Neutropenia and G-CSF in lymphoproliferative diseases
por: Ria, Roberto, et al.
Publicado: (2013)

Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
por: Riedel, Amy, et al.
Publicado: (2007)

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients
por: Jiang, Yantao, et al.
Publicado: (2023)

PEG‐rhG‐CSF for prophylaxis of neutropenia after chemotherapy in patients with non–small cell lung cancer: A multicenter, prospective, randomized study
por: Sun, Xu‐Sheng, et al.
Publicado: (2022)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
Publicado: (2019)

Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature
por: Masood, Nehal, et al.
Publicado: (2008)

Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
por: Tonra, James R., et al.
Publicado: (2019)

Respiratory status deterioration during G-CSF-induced neutropenia recovery
por: Karlin, L, et al.
Publicado: (2005)

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone
por: Sung, Anthony D., et al.
Publicado: (2013)

Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
por: O' Neill, Eimear, et al.
Publicado: (2021)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
por: Tirelli, Umberto, et al.
Publicado: (2020)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis
por: Li, Edward, et al.
Publicado: (2021)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

Utilization of G-CSF and GM-CSF as an alternative to discontinuation in clozapine-induced neutropenia or leukopenia: A case report and discussion
por: Karst, Allison, et al.
Publicado: (2018)

The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas
por: Tesfa, Daniel, et al.
Publicado: (2021)

Comparison of Long-Acting G-CSF (PD-Lasta) with Short-Acting G-CSF (PD-Grastim) in Neutrophil Recovery Following Consolidation Chemotherapy with High-Dose Cytarabine in Acute Myeloid Leukemia: A Randomized Clinical Trial
por: Esfandbod, Mohsen, et al.
Publicado: (2021)

Neutropenia and Infection Prophylaxis in Childhood Cancer
por: Villeneuve, Stephanie, et al.
Publicado: (2022)

Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19
por: Taha, Muhanad, et al.
Publicado: (2020)

G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
por: Cardot-Ruffino, Victoire, et al.
Publicado: (2023)

Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study
por: Ravangard, Ramin, et al.
Publicado: (2017)

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
por: Mądry, Radosław, et al.
Publicado: (2016)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
por: Weycker, Derek, et al.
Publicado: (2015)

Novel Point Mutation in the Extracellular Domain of the Granulocyte Colony-Stimulating Factor (G-Csf) Receptor in a Case of Severe Congenital Neutropenia Hyporesponsive to G-Csf Treatment
por: Ward, Alister C., et al.
Publicado: (1999)

Adjuvant Chemotherapy for Breast Cancer in a Patient with Primary Autoimmune Neutropenia
por: Trus, Michael, et al.
Publicado: (2013)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
por: Cooper, Katy L, et al.
Publicado: (2011)

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
por: Aapro, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dcacljoebuhndckp1g19abfqh6